Kirsteen Maclean, Principal Scientist, NeoGenomics discussed her company’s MultiOmyx platform, a dedicated spatial proteomics platform that transitioned from region of interest analysis to whole slide imaging.
Maclean mentioned that the company supports three platforms for spatial analysis: Rare Cyte’s Cyte Finder, Akoya PhenoImager, and NanoString GeoMx. These platforms are used for various clinical trials and preclinical approaches. NeoGenomics provides spatial support for therapies like CAR-T, CAR-NK, CAR-macrophages and targeted therapies. Their lab services include immunohistochemistry, flow cytometry, cytogenetics, and spatial genomics.
NeoGenomics uses whole slide imaging to analyse entire tissue sections rather than selected regions, allowing more robust and reproducible insights. The imaging pipeline includes creating virtual H&E images, selecting tumour-relevant regions with pathologists, and applying AI-driven image segmentation and biomarker classification.
Validation was another major theme tackled in this presentation. They demonstrated high concordance between traditional ROI-based workflows and the new whole slide imaging approach, with correlation values above 0.9. This level of agreement shows the new method's reliability compared to previously published data.
Moreover, reproducibility was also tested using repeated runs of the same assay on serial tumour sections over several months. The results showed very low variance and high consistency which reiterates the platform's suitability for clinical trials.
Maclean also highlighted the importance of spatial context, especially neighbourhood and proximity analysis of cell types such as T cells near immunosuppressive environments. This kind of data is key for understanding tumour-immune interactions. Recent publications including a case study from BioNTech used MultiOmyx which correlated well with CT imaging pre and post biopsy. Carisma Therapeutics used NeoGenomics’ tools to examine CAR macrophages and the spatial quantification of their specific assets.
